Clinical Trial Update: Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease [Phase 3]

View source ↗

Summary

Phase 3 study assessing darbepoetin alfa dosing for correcting anemia in pediatric chronic kidney disease; study terminated with posted results in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• darbepoetin alfa (darbepoetin alfa)

Snippet

Sponsor: Amgen | Conditions: Anemia, Chronic Kidney Disease | Phase 3 | Status: TERMINATED | Results posted: 2015-03-31